Table 1.
Outcomes of patients assessed by FDG PET CT and the differentially culturable tubercle bacilli (DCTB) assay at month 6 after successful anti-TB therapy.
| PID | DCTB | Outcome | Response pattern | Intensity rank | TGAI | Total cavity volume (mL) |
|---|---|---|---|---|---|---|
| 338 | POS | Relapse | Mixed | Very high | 43007.0 | 39.9 |
| 267 | POS | Cured | Mixed | Very high | 38304.0 | 30.9 |
| 253 | POS | Cured | Resolved | Minimal | 70.36 | 0.0 |
| Median (range) | 38304.00 (70.4–43007) | 30.9 (0–39.9) | ||||
| 332 | Cured | Mixed | High | 4598.2 | 0.0 | |
| 351 | Cured | Mixed | Moderate | 2853.4 | 0.0 | |
| 250 | Cured | Mixed | Very high | 620.0 | 62.9 | |
| 334 | Cured | Improved | Very high | 9757.8 | 19.4 | |
| 375 | Cured | Improved | Very high | 9562.6 | 1.8 | |
| 291 | Cured | Improved | Moderate | 6349.8 | 5.9 | |
| 392 | Cured | Improved | Very high | 6109.6 | 0.0 | |
| 382 | Cured | Improved | Very high | 2795.4 | 2.8 | |
| 335 | Cured | Improved | High | 2265.7 | 15.7 | |
| 357 | Cured | Improved | Moderate | 634.9 | 0.0 | |
| 278 | Cured | Improved | Mild | 585.6 | 0.0 | |
| 315 | Cured | Improved | Moderate | 235.5 | 0.0 | |
| 300 | Cured | Improved | High | 173.2 | 0.0 | |
| 314 | Cured | Improved | Mild | 151.7 | 0.0 | |
| 273 | Cured | Resolved | None | 1681.9 | 0.0 | |
| 365 | Cured | Resolved | Minimal | 951.7 | 0.0 | |
| 318 | Cured | Resolved | Minimal | 306.2 | 0.5 | |
| 306 | Cured | Resolved | Minimal | 213.8 | 0.0 | |
| 359 | Cured | Resolved | Minimal | 168.2 | 2.8 | |
| Median (range) | 793.27 (151.7–9757.8) | 0.0 (0.0–62.9) | ||||
| 22.7% mixed | ||||||
| 50% improved | ||||||
| 27.3% resolved |
PET CT responses were classified according to total glycolytic activity (TGAI), cavity, response pattern, and intensity rank. Highlights in red show patients classified as higher risk according to PET CT cut offs (TGAI ≥ 600, cavity volume ≥ 7 mL, mixed response, and very high intensity rank).